Deirdre Somers Biography and Net Worth

Director of Enfusion

Deirdre Somers is an experienced asset management industry executive, having spent her more than 30-year career as the former CEO of a securities exchange and as an independent non-executive director, committee member, and chairman, among other roles. Somers has both international experience and industry knowledge in financial products, market structure, and EU regulation, as well as in corporate actions and public market transitions.

Somers is currently an independent non-executive director (INED) and committee member of Aquis Exchange PLC, Blackrock iShares, Cancer Trials Ireland (Chair), Episode Inc, and Kenmare Resources plc.

What is Deirdre Somers' net worth?: The estimated net worth of Deirdre Somers is at least $465,093.00 as of January 13th, 2025. Ms. Somers owns 41,675 shares of Enfusion stock worth more than $465,093 as of April 2nd. This net worth approximation does not reflect any other assets that Ms. Somers may own. Learn More about Deirdre Somers' net worth.
How do I contact Deirdre Somers?: The corporate mailing address for Ms. Somers and other Enfusion executives is , , . Enfusion can also be reached via phone at 312-253-9800 and via email at brian.murphy@icrinc.com. Learn More on Deirdre Somers' contact information.
Has Deirdre Somers been buying or selling shares of Enfusion?: Deirdre Somers has not been actively trading shares of Enfusion during the last ninety days. Most recently, Deirdre Somers sold 1,637 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.53, for a transaction totalling $17,237.61. Following the completion of the sale, the director now directly owns 41,675 shares of the company's stock, valued at $438,837.75. Learn More on Deirdre Somers' trading history.
Who are Enfusion's active insiders?: Enfusion's insider roster includes Bronwen Bastone (Chief People Officer), Matthew Campobasso (General Counsel), Dan Groman (Chief Technology Officer), Bradley Herring (CFO), Roy Luo (Director), Oleg Movchan (CEO), Neal Pawar (Chief Operating Officer), and Deirdre Somers (Director). Learn More on Enfusion's active insiders.
Are insiders buying or selling shares of Enfusion?: During the last twelve months, insiders at the sold shares 29 times. They sold a total of 160,582 shares worth more than $1,648,833.48. The most recent insider tranaction occured on March, 6th when CEO Oleg Movchan sold 11,452 shares worth more than $130,438.28. Insiders at Enfusion own 36.4% of the company. Learn More about insider trades at Enfusion.
Information on this page was last updated on 3/6/2025.

Deirdre Somers Insider Trading History at Enfusion

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/13/2025	Sell	1,637	$10.53	$17,237.61	41,675
6/14/2024	Sell	4,629	$8.40	$38,883.60	43,312
1/10/2024	Sell	1,770	$8.65	$15,310.50	34,471

Deirdre Somers Buying and Selling Activity at Enfusion

Enfusion Company Overview

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

Today's Range

Now: $11.16

$11.07

$11.17

50 Day Range

MA: $11.18

$11.01

$11.50

2 Week Range

Now: $11.16

$7.83

$11.80

Volume

496,529 shs

Average Volume

555,547 shs

Market Capitalization

$1.44 billion

P/E Ratio

279.07

Dividend Yield

N/A

Beta

0.95